PP14767/09/2012(030761)

## **Genting Plantations Berhad**

## "The Worst is Over"

## **Result Review**

- Actual vs expectations. Genting Plantations Berhad (GenPlant) registered a lower sales turnover of RM570 million (-10% y-o-y) due to lower FFB production in Plantation-Malaysia as well as lower land sales during the period. Operating profit fell in tandem with weaker sales by 11% y-o-y to RM112 million while PBT declined to RM91 million (-26% y-o-y) as a result of lower crop yields and higher manuring costs. 1H16 PAT came in below our expectation, accounting only 27% of our full year forecast owing to 41% y-o-y plunge in net profit in 1Q16 as a result of weak CPO prices and waning FFB production.
- Dividend payout. The board declared an interim dividend of 2 sen during the quarter, half sen lower than previous corresponding period. We expect dividend yield for FY16 to stay below 2%.
- on the road of recovery. Along with the rebound in CPO prices, GenPlant staged a firmed recovery after the lurching 1Q16 results. 2Q16 revenue lifted from RM261 million to RM309 million (+18% q-o-q) while PBT jumped 36% q-o-q to RM52 million as average CPO price and PK price rose by 14% q-o-q and 26% q-o-q, respectively. Upstream plantation revenue in Malaysia recorded a strong 36% q-o-q growth with same segment PBT expanded by 39% due to favourable CPO and Palm Kernel (PK) prices.

However, property segment continued to trim the bottom line growth after witnessing 16% q-o-q decline to RM35 million in 2Q16. This was due to the absence of sizable land sales which was reported for the same period last year. PBT in property segment plunged in tandem with lower sales turnover by 42% q-o-q to merely RM11.4 million in 2Q16.

Research Team research@mna.com.my 03-22821820 ext. 257, 229, 221, 249, 258

## Friday, August 26, 2016

HOLD (TP: RM10.19)

| Current Price (RM)         | RM10.64 |
|----------------------------|---------|
| New Target Price (RM)      | RM10.19 |
| Previous Target Price (RM) | RM11.59 |
| Previous Recommend.        | HOLD    |
| Upside To Target Price     | -4.2%   |
| Dividend Yield             | 1%      |
|                            |         |

#### Stock Code

| Bloomberg | GENP | MK |
|-----------|------|----|
|-----------|------|----|

#### Stock & Market Data

| Listing                      | MAII    | N MARKET   |
|------------------------------|---------|------------|
| Sector                       | F       | Plantation |
| Shariah Compliance           |         | Yes        |
| Issued Shares (mn)           |         | 791.6      |
| Market Cap (RM mn)           |         | 8,423.0    |
| YTD Chg In Share Price       |         | 0.54%      |
| Beta (x)                     |         | 1.00       |
| 52-week Hi/Lo (RM)           | RM11.56 | RM8.93     |
| 3M Average Volume (000'shrs) |         | 306.9      |
| Estimated Free Float         |         | 23.7%      |

## **Major Shareholders**

| Genting | 51.4% |
|---------|-------|
| EPF     | 12.9% |
| KWAP    | 5.1%  |

- Fall of inventory level. Palm oil stockpiles in Malaysia declined in July as exports surged to the highest this year. Inventories dropped 0.2% to 1.77 million MT at July 2016. Palm oil production rose 3.5% to 1.59 million MT while exports soared 21% to 1.38 million MT, the highest since December 2015. Demand from China is set to recover ahead of its major Mid-Autumn festival, potentially boosting demand for edible oil used to make seasonal treats like mooncakes. Concerns over heavy rains caused by La Nina may also hamper harvests that results in the occurrence of stock up activity in advance.
- **Higher production costs offset turnaround CPO prices.** Average CPO and PK prices rebounded by 19% y-o-y and 52% y-o-y, to RM2,588 and RM2,344, respectively on the back of a decline in national palm oil inventory levels and supply tightness in lauric oils market. PBT fell to RM52 million (-6% y-o-y) in 2Q16 owing to higher manuring costs and fall of yields that collectively outweighed the impact of higher palm product selling prices. Notwithstanding that, on quarter-on-quarter basis, PBT improved substantially by 36% q-o-q amid stronger palm product selling prices (CPO increased 14% q-o-q; PK increased 26% q-o-q) and higher FFB production (+4% q-o-q to 315,000 MT). In conjunction with the 12% decline in EBITDA for 1H16, GenPlant's PBT margin was subsequently shaved to 16% or -3% y-o-y.
- Outlook. Consumption pick-up in edible oil has started to pare down high inventory stockpile
  nationwide. Coupled with stocking up by traders ahead of potential shortage over the concerns of
  harvesting amid raining seasons, the CPO prices are expected to rise and hover between RM2,500RM2,800 by end-2016. The fading El Nino effect is anticipated to induce crop yields and increase
  FFB production moving forward. We expect GenPlant's FFB to hit 1.6 million MT and 1.9 million
  MT in FY16 and 17, respectively.

Property segment is expected to remain soft for the next 2 years in the event of cooling measures by the government including stricter loan approval for applicants and the tax on property gains. Notwithstanding that, as the land value appreciate over the course, the property division will continue to thrive once the market sentiment improves. Of note, mature landbank with low yielding old trees would be converted to property development in GenPlant.

- Changes of forecast. We have changed our FY16/17 earnings forecast to incorporate the exceptionally poor result in 1Q16 due to adverse weather condition and weak CPO prices. PAT has been trimmed by 22%/15%/14% in FY16/17/18 to RM187 million/RM218 million/RM293 million, respectively.
- Valuation. In view of the changes in earnings forecast, we trim our previous target price of RM11.59 and arrive our new TP at RM10.19 based on SOP valuation. We maintain our target PER of 24x pegged to FY17 earnings for the plantation segment and maintain the forecasts in property and biotech segments. Maintain HOLD.

**Exhibit 1: SOP valuation** 

| Segments              | Valuation basis | Multiples | Value (RM'm) |  |
|-----------------------|-----------------|-----------|--------------|--|
| Plantation            | FY17 PER        | 24.2x     | 5,276        |  |
| Property              | RNAV            | 0.5x      | 3,354        |  |
| Biotech               | BV              | 1x        | 288          |  |
| Downstream            | BV              | 1x        | 256          |  |
| Less: Net debt        | 2Q FY16         |           | -822         |  |
| SOP value             |                 |           | 8,352        |  |
| Share outstanding (m) | FY17E           |           | 820          |  |
| Target Price (RM)     |                 |           | 10.19        |  |

Source: M&A Securities

Exhibit 2: Palm Products ASP & FFB

| ASP (RM)                 | 1Q15  | 2Q15  | 1Q16  | 2Q16  | q-o-q | у-о-у       |
|--------------------------|-------|-------|-------|-------|-------|-------------|
| ASP-CPO                  | 2,246 | 2,171 | 2,273 | 2,588 | 14%   | 19%         |
| ASP-PK                   | 175   | 1,538 | 1,866 | 2,344 | 26%   | <b>52</b> % |
|                          |       |       |       |       |       |             |
| FFB production ('000 MT) | 353   | 405   | 315   | 329   | 4%    | -19%        |

Source: M&A Securities


**Exhibit 3: Financial Summary** 

| VF: December (DM million) 2044A 2045A 2046F 2047F 204 |       |       |       |       |       |  |
|---|-------|-------|-------|-------|-------|--|
| YE: December (RM million)                             | 2014A | 2015A | 2016F | 2017F | 2018F |  |
| Revenue   | 1,643 | 1,375 | 1,527 | 1,719 | 2,106 |  |
| EBITDA  | 591   | 386   | 504   | 543   | 687   |  |
| EBIT  | 513   | 276   | 377   | 389   | 506   |  |
| Finance cost  | -11   | -50   | -67   | -59   | -63   |  |
| PBT   | 520   | 247   | 330   | 356   | 472   |  |
| Tax   | -136  | -71   | -90   | -100  | -131  |  |
| PAT   | 384   | 177   | 240   | 256   | 341   |  |
| EPS (sen)   | 49    | 24    | 27    | 30    | 40    |  |
| Minority interest                                     | 7     | -13   | -7    | -13   | -14   |  |
| PATMI   | 377   | 190   | 247   | 269   | 355   |  |
| PBT margin  | 32%   | 18%   | 22%   | 21%   | 22%   |  |
| PAT margin  | 23%   | 13%   | 16%   | 15%   | 16%   |  |

Source: Company, M&A Securities

**Exhibit 4: Results Comparison** 

| FYE DEC (RM<br>million) | 2Q15 | 1Q16 | 2Q16 | Q-o-Q       | Y-o-Y | 6M15 | 6M16 | Y-o-Y       |
|-------------------------|------|------|------|-------------|-------|------|------|-------------|
| Revenue                 | 306  | 261  | 309  | 18%         | 1%    | 630  | 570  | -10%        |
| EBITDA                  | 114  | 74   | 88.6 | 20%         | -23%  | 180  | 163  | -10%        |
| D&A                     | 54   | 25   | 25   | 1%          | -53%  | 54   | 50   | <b>-7</b> % |
| EBIT                    | 60   | 49   | 63   | <b>29</b> % | 5%    | 126  | 112  | -11%        |
| Finance cost            | -9   | -17  | -16  | <b>-2</b> % | 86%   | -14  | -33  | 137%        |
| PBT                     | 56   | 38   | 52   | 36%         | -6%   | 122  | 91   | -26%        |
| Tax                     | -17  | -10  | -15  | 40%         | -16%  | -36  | -25  | -30%        |
| PAT                     | 38   | 28   | 38   | 34%         | -1%   | 86   | 66   | -24%        |
| PATMI                   | 40   | 27   | 41   | 51%         | 2%    | 93   | 68   | -27%        |
| EPS                     | 5    | 3    | 5.20 | 51%         | 0%    | 12   | 9    | -28%        |
| EBITDA margin           | 37%  | 28%  | 29%  | 0%          | -9%   | 29%  | 29%  | 0%          |
| EBIT margin             | 20%  | 19%  | 20%  | 2%          | 1%    | 20%  | 20%  | 0%          |
| PBT margin              | 18%  | 15%  | 17%  | 2%          | -1%   | 19%  | 16%  | -3%         |
| Net profit margin       | 13%  | 10%  | 13%  | 3%          | 0%    | 15%  | 12%  | -3%         |



# M&A Securities

### STOCK RECOMMENDATIONS

BUY Share price is expected to be  $\geq +10\%$  over the next 12 months.

TRADING BUY Share price is expected to be  $\geq +10\%$  within 3-months due to positive newsflow. HOLD Share price is expected to be between -10% and +10% over the next 12 months.

SELL Share price is expected to be  $\geq -10\%$  over the next 12 months.

#### SECTOR RECOMMENDATIONS

OVERWEIGHT The sector is expected to outperform the FBM KLCI over the next 12 months.

NEUTRAL The sector is expected to perform in line with the FBM KLCI over the next 12

months.

UNDERWEIGHT The sector is expected to underperform the FBM KLCI over the next 12 months.

#### DISCLOSURES AND DISCLAIMER

This report has been prepared by M&A SECURITIES SDN BHD. Readers should be fully aware that this report is for informational purposes only and no representation or warranty, expressed or implied is made as to the accuracy, completeness or reliability of the information or opinion contained herein. The recommendation and opinion are based on information obtained or derived from sources believed to be reliable.

This report contains financial forecast/projection based on our assumptions which may defer from the actual financial results announced by the companies under coverage. All opinions, estimates and assumptions are subject to change without notice. Analysts will initiate, update and cease coverage solely at the discretion of M&A SECURITIES SDN BHD.

Investors are to be cautioned that value of any securities invested may fluctuate from time to time. We advise investors to seek financial, legal and other advice for investing based on the recommendation of our report as we have not taken into account each investors' specific investment objectives, risk tolerance and financial position.

This report is not, and should not be construed as, an offer to buy or sell any securities or other financial instruments. M&A SECURITIES SDN BHD can accept no liability for any consequential loss or damage whether direct or indirect. Investment should be made at investors' own risks.

M&A SECURITIES SDN BHD and INSAS GROUP of companies, their respective directors, officers, employees and connected parties may have interest in any of the securities mentioned and may benefit from the information herein. M&A SECURITIES SDN BHD and INSAS GROUP of companies and their affiliates may provide services to any company and affiliates of such companies whose securities are mentioned herein. This report may not be reproduced, distributed or published in any form or for any purpose.

M & A Securities Sdn Bhd (15017-H) (A wholly-owned subsidiary of INSAS BERHAD) A Participating Organisation of Bursa Malaysia Securities Berhad

Principal Office: Level 1,2,3 No.45 & 47,43-6 The Boulevard, Mid Valley City, Lingkaran Syed Putra, 59200 Kuala Lumpur

Tel: +603 - 2282 1820 Fax: +603 - 2283 1893

Website: www.mnaonline.com.my